Funktsionaalse genoomika töögrupp

Meie töögrupp kasutab erinevaid oomika ja terviseandmete andmekihte, et uurida inimeste haiguste eelsoodumust, väljakujunemist ja progresseerumise trajektoore. Meie eesmärk on selgitada välja haiguste ja muude fenotüüpide geneetilised ja molekulaarsed alused. Selle saavutamiseks me kasutame mitmesuguseid suure läbilaskevõimega arvutus- ja geneetilise epidemioloogia tehnikaid, et tuvastada, valideerida ja annoteerida geneetika ja haiguste seoseid, keskendudes võimalikele põhjuslikele variantidele ning nende molekulaarsetele mehhanismidele ja mõjudele. Samuti oleme huvitatud molekulaarsete endofenotüüpide geneetilisest arhitektuurist ning sotsiaalsete ja käitumuslike fenotüüpide geneetikast. Lisaks me integreerime mudelorganismidega tuvastatud eksperimentaalseid teadmisi inimeste oomika-analüüsidega, et avastada haiguste aluseks olevaid mehhanisme, pöörates erilist tähelepanu haiguste ja kronotüübi seosele.

Priit Palta
Grupi juht: Priit Palta, PhD (Bioinformaatika), professor
Priit Palta on genoomika instituudi asedirektor, Eesti Geenivaramu arenduskeskuse juht, rakendusliku genoomika professor ja funktsionaalse genoomika töörühma juht

Peamised uurimisvaldkonnad: rakenduslik genoomika, arvutuslike meetodite arendamine, inimese komplekshaiguste geneetika ja genoomika

Grupi liikmed

Urmo Võsa

Urmo Võsa

PhD (Molekulaarbioloogia)

CV

Urmo Võsa

Teadur

Urmo Võsa on genoomika ja molekulaarbioloogia taustaga teadlane kelle uurimistöö keskendub komplekshaiguste molekulaarsete aluste mõistmisele funktsionaalse genoomika andmestike abil.

Erik Abner

Erik Abner

PhD (Biomeditsiin)

CV

Erik Abner

Teadur

Erik Abner on genoomika ja molekulaarbioloogia taustaga teadlane, kelle uurimistöö keskendub kodeerivate geenivariantide funktsionaalsele tõlgendamisele ja komplekshaiguste geneetilise tausta uurimisele Eesti geenivaramu andmestikus. Ta tegeleb aktiivselt ka teaduse populariseerimisega ja peab oluliseks teadlaste nähtavust ühiskonnas.

Peamised uurimissuunad: kodeerivate variantide tõlgendamine, funktsionaalne genoomika, populatsioonigeneetika, molekulaarbioloogia

Jaanika Kronberg

Jaanika Kronberg

PhD (Bioteadused)

CV

Jaanika Kronberg

Süsteemibioloogia teadur

Peamised uurimissuunad: süsteemibioloogia, eksposoom

Uku Vainik

Uku Vainik

PhD (psühholoogia)

CV

Uku Vainik

Käitumisgeneetika professor & kaasprofessor

Peamised uurimissuunad: rasvumine ja üle söömine, isiksus, vaimsed võimed, aju struktuur, Internetis andmete kogumine, põhjuslikksue modelleerimine geenide abil.

Kanwal Batool

Kanwal Batool

MSc (Molekulaargeneetika)

CV

Kanwal Batool

Doktorant, Nooremteadur (Juhendajad: Erik Abner, Tõnu Esko)

Anastasiia Alekseienko

Anastasiia Alekseienko

MSc (Bioinseneeria)

CV

Anastasiia Alekseienko

Doktorant, nooremteadur (Juhendajad: Priit Palta, Erik Abner, Jaanika Kronberg, Urmo Võsa )

Andres Veidenberg

Andres Veidenberg

MSc (bioinformaatika)

CV

Andres Veidenberg

Bioinformaatika spetsialist

Birgit Malken

Birgit Malken

MA (psühholoogia)

CV

Birgit Malken

Doktorant, tervisekäitumisgeneetika nooremteadur (Juhendajad: Uku Vainik, Priit Palta)

Teele Palumaa

Teele Palumaa

PhD (Biomeditsiin)

CV

Teele Palumaa

Oftalmoloogia ja genoomika teadur

Teele Palumaa teadustöö keskendub une ja tsirkadiaanrütmide rollile inimeste tervises ning silmahaiguste molekulaarsete ja geneetiliste mehhanismide uurimisele.

Peamised uurimissuunad: tsirkadiaanbioloogia, oftalmoloogia, funktsionaalne genoomika, populatsioonigeneetika

Lehte Türk

Lehte Türk

MSc (geenitehnoloogia)

CV

Lehte Türk

Bioinformaatika spetsialist

Projektid ja rahastus

Led by Prof. Priit Palta, this project aims to develop a comprehensive catalogue of genetic effects on disease phenotypes, including ICD10 diagnostic, ATC drug, NOMESCO procedure, and LOINC lab value codes. So far, we have finished GWAS for 5,522 diseases, defined based on the ICD codes. We also performed sex-specific GWAS for 602 diseases and we continue with post-GWAS analyses to prioritise and interpret the results.

Led by Priit Palta, in collaboration with Kaur Alasoo, this project involves conducting a GWAS meta-analysis on 249 circulating metabolite traits from the Estonian Biobank and UK Biobank datasets, with a combined sample size of 619,372. This is the largest metabolite GWAS to date and will significantly aid GWAS interpretation and method development.

In 2024, we completed GWAS analyses for both biobanks and made the combined meta-analysis results publicly available here with the pre-print of our findings available here.

Led by research fellow Urmo Võsa, the project aims to comprehensively characterize the genetics of blood gene expression via highly powered consortium meta-analyses (https://www.eqtlgen.org). This year was pivotal, as we finalized all the cohort-level analyses and conducted genome-wide expression quantitative trait meta-analysis in 43,301 samples from 51 datasets, representing ~8x power increase compared to previous similar studies. The initial results were selected for oral presentation at the American Society of Human Genetics meeting, and currently, we are engaged with numerous interpretative analyses, as well as manuscript writing and collaborative sub-projects.

A European project led by the Utrecht University, the aim of this project is to develop tools and datasets that can be used to study exposome-health associations in cardiometabolic and pulmonary diseases. The exposome analysis of Estonian Biobank data is led by Jaanika Kronberg. We are analysing associations of external exposome with health outcomes and different omics layers in the Estonian Biobank and participate in meta-analyses with other partners of the project.

DISCERN is a European project coordinated by IARC. The aim of the project is to study the causes of three poorly understood cancers: renal, colorectal and pancreatic. The PI in the University of Tartu is Elin Org.

Jaanika Kronberg is leading exposome analyses in the University of Tartu in relation to cancer outcomes.

The EU project CVDLINK (led by research fellow Urmo Võsa) aims to improve the prediction of the risk for cardiovascular diseases via federated artificial intelligence methods. This project has reached the end of the first year: together with consortium partners, we conducted preparatory groundwork, which enable us to proceed with the project plan and analyses. We participated in the actions of four work packages and led one task, which coordinated the acquisition of ethical committee approvals for all participating hospitals and biobanks.

The EU project CLARITY (led by research fellow Erik Abner) aims to uncover the mechanisms linking respiratory syncytial virus (RSV) infections and genetic predisposition to chronic immune-mediated diseases (CIMDs), such as asthma. The project seeks to identify genetic and viral factors associated with severe bronchiolitis, understand molecular mechanisms driving virus-induced CIMDs, and develop prevention strategies and therapeutic targets.

The EU project WISDOM (led by research fellow Erik Abner) focuses on developing AI-mediated predictive models to enhance the diagnosis, treatment, and management of chronic autoimmune diseases, including multiple sclerosis, myasthenia gravis, and rheumatoid arthritis. Our role is to validate the AI models developed by partners using Estonian Biobank data and ensure their applicability across diverse populations.

Led by research fellow Teele Palumaa and funded by the Marie Skłodowska-Curie postdoctoral fellowship, explores the link between circadian rhythms and myopia, a condition expected to affect half the global population by 2050. The project combines animal model studies at Emory University with human genetics research at EstBB. Initial findings suggest that altering circadian rhythms influences myopic eye growth, involving GABA and cholinergic signalling in the retina.

A European partnership dedicated to advancing public health research through transnational collaboration will be led by Prof. Uku Vainik. This project aims to enhance NAD metabolism to prevent pathological brain aging. In EstBB, we will analyse the role of NAD in cognitive abilites.

Kas leidsite vajaliku informatsiooni? *
Aitäh tagasiside eest!